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Abstract
A new series (6) of  C5-curcuminoid derivatives (2E,6E-2,6-dibenzylidene-4-hydrox-
ycyclohexanones) is described here with their evaluation for in vitro antiproliferative 
activities. Evaluation of 31 compounds against human A2780 (ovarian), C33A (cer-
vix) and MDA-MB-231 (breast) cancer cell lines was performed to obtain structure 
activity relation data. The best performer was (2E,6E)-2,6-bis(3′-nitrobenzylidene)-
4-hydroxycyclohexanone (6h) with  IC50 values of 0.68  μM (A2780), 0.69  μM 
(C33A) and 0.92 μM (MDA-MB-231) compared to cisplatin with 1.30 μM, 3.69 μM 
and 19.13  μM, respectively. According to calculated physicochemical properties 
some members in series 6, namely (2E,6E)-2,6-bis[(4′-pyridinyl)methylene]-4-hy-
droxycyclohexanone (6p)  [IC50 = 0.76  μM (A2780), 2.69  μM (C33A), 1.28  μM 
(MDA-MB-231)] seem to have improved bioavailability compared to curcumin. 
Selected members of series 6 were involved in circular dichroism spectroscopic 
measurements in order to determine their interaction with natural DNA. Based on 
these data, we conclude that these derivatives do not bind to DNA in vitro. A pro-
posal is summarized based on mass spectrometric assessment for fingerprint analy-
sis in biological research of such  C5-curcuminoids.
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Introduction
Although there has been great progress in the development of treatment and 
prevention, cancer remains a major worldwide health problem. Because of an 
increase in worldwide mortality with growing prevalence, according to WHO 
reports [1], the successful treatment of cancer is still a challenge this century. 
Chemotherapy alongside surgical, radiological and biological treatment of can-
cer played a fundamental role for many decades. Hence, there is a current need 
to search for newer and more active anticancer compounds in pharmaceutical 
research fields. The research for mimics of natural materials is such a field in 
pharmaceutical science and is considered one of the major sources of lead mol-
ecules and drug candidates [2].
Plants used as spices, flavoring and coloring agents in the kitchen (nutraceu-
ticals), or as preventive/curing additives in the Ayurvedic and folkloric medici-
nal practice (pharmaceuticals) are excellent sources for natural compounds. Such 
plants are common in the Zingiberaceae (ginger) family. Their powdered rhi-
zome (a modified subterranean stem), as a yellow powder known as turmeric, 
has been used for thousands of years in Asian countries. For example, plants such 
as Curcuma longa L. and/or Curcuma domestica L. are also in use to prepare 
the well-known Indian spice turmeric currently. The major component of tur-
meric is its secondary metabolite, curcumin (1). Extensive research has shown 
that curcumin exhibits many different pharmacological effects and has a num-
ber of molecular targets with multiple pathways as an antiproliferative molecule 
[3, 4], although curcumin is remarkably non-toxic and has promising anticancer 
activities. Clinical studies indicate that its poor bioavailability and pharmacoki-
netic profiles due to instability under physiological conditions is a disadvantage 
[3]. Curcumin (diferuloylmethane), 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-
heptadien-3,5-dion contains a  C7 ß-diendione linkage (1,6-heptadien-3,5-dion) 
between the two arylidene groups in its structure. It was believed for a long time 
that natural curcuminoids (including the metabolites of curcumin) are exclusively 
 C7-curcuminoids. However, along with curcumin a  C5-curcuminoid was also 
isolated from both Curcuma longa and Curcuma domestica [5, 6]. This natural 
 C5-curcuminoid, 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one, as a 
truncated analogue of curcumin contains a  C5 ß-dienone linker (1,4-pentadiene-
3-one) between the two benzylidene cores in its structure. This compound and 
its related derivatives proved to be more potent anticancer molecules compared 
to curcumin [7]. There is a great number of cyclic  C5-curcuminoid analogues 
with excellent antiproliferative potential among the synthetic curcuminoids 
with the general structure 2 (Fig.  1). Structural modifications of curcumin and 
 C5-curcuminoids focusing on enhancing their bioactivities have been investigated 
intensively during the last couple of decades. Numerous studies have been con-
ducted, for example about the (3E,5E)-3,5-dibenzylidene-4-piperidone synthetic 
 C5-curcuminoid family [8–18]. It is well known about these 4-piperidone deriva-
tives that they exhibit higher cytotoxicity than curcumin towards different tumor 
cell lines such as breast, prostate, cervix, melanoma [3]. Compound EF24, for 
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example (Fig. 1), showed high activity against cisplatin-resistant human ovarian 
cancer cells. The inhibitory effect of EF24 on cell-proliferation, as is common 
with such compounds, is due to its inductive ability to G2/M arrest and apoptosis 
by increasing phosphorylated phosphatase and tensin homolog (PTEN) expres-
sion [19]. In addition to G2/M arrest and apoptosis induction, these 4-piperidone 
derivatives show differential cytotoxicity: they are less toxic to non-cancerous 
cells when compared to cancer cells [8, 13–16].
Another crucial advantage of these synthetic  C5-curcuminoids is that a number of 
them are able to revert multi-drug resistance (MDR) [17, 20, 21]. Moreover, there 
are reports on the in vivo tolerability and the lack of acute toxicity of these curcumi-
noids on rodents. There are compounds in this family that proved to be safe and did 
not cause mortality or convulsion in mice during a 2-week period of oral adminis-
tration in 100–500  mg/kg dosage [22]. A number of  C5-curcuminoids possessing 
the 1,4-pentadiene-3-one moiety have different modes of action, such as inducing 
apoptosis, cell cycle arrest, inhibiting the biosynthesis of polypeptides fundamental 
to tumor-progression, affecting mitochondrial respiration and stimulation/inhibition 
of certain enzymes playing role in tumor-growth [23]. Further, there is continuing 
debate on the binding or intercalation of curcumin onto DNA [24, 25] as to whether 
binding or intercalation would result in DNA damage in healthy cells as a dramatic 
side effect. There are scientific facts against this “DNA damage” theory in that cur-
cumin binds to the minor groove of DNA, albeit weakly [26]. In another example, 
incubation with calf thymus DNA had little effect on either UV/Vis or fluorescence 
spectra of curcumin [27].
Based on the above description and the literature available in this field, we can 
say that the number of reports on the structural modifications on  C5-curcuminoids is 
very high. So far, however, none of these drug-candidates passed into drug-develop-
ment study or clinical trials.
Fig. 1  Curcumin and synthetic cyclic  C5-curcuminoids
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In view of the considerations above, we have decided to synthetize new, cyclic 
derivatives of natural  C5-curcuminoids with the general structure 2 (Fig.  1). In 
one of our previous publications, we compared the antiproliferative activity of 25 
arylidene cyclanones where the ketone scaffold was cyclopentanone, cyclohex-
anone, 1-indanone, 1-tetralone or 4-piperidone (2, X = CH2, NH or N-alkil) [28]. 
Their cytotoxicity against four human adherent cancer cell lines was evaluated. The 
cytotoxicity screen revealed that the diarylidene derivatives in general dominate the 
monoarylidene enones and, simultaneously, the nitrogen containing heterocycles 
display higher inhibition in cell-proliferation compared with the homocyclic ana-
logs. The best performer was N-(γ-oxobutyl)-(3E,5E)-3,5-bis(4′-chlorobenzylidene)-
4-piperidone (3, Fig. 1) with  IC50 values of 0.438–1.048 μM. In the present article 
we describe the synthesis and comparative pharmacological evaluation of cyclic 
 C5-curcuminoid analogues 2 (X = NCH3,  CHCH3 or CHOH).
Experimental
Chemistry
Chemicals, solvents and reagents for the study were purchased from Alfa Aesar, 
Molar and Merck Ltd (Budapest, Hungary). Melting points were determined on 
a Barnstead-Electrothermal 9100 apparatus and are uncorrected. Silica gel 60 
(0.2–0.5 mm, MERCK) was used for column chromatography and pre-coated silica 
gel 60 (F-254, MERCK) plates for TLC.
NMR: 1H- and 13C-NMR spectra were obtained using a Varian UNITY INOVA 
400 WB spectrometer. Chemical shifts are referenced to the residual solvent signal. 
Measurements were run at a probe temperature of 298  K in  CDCl3 or DMSO-d6 
solutions. All the 1H- and 13C-NMR spectra were in accordance with the expected 
structures.
MS: The sample solutions were prepared by dissolving 0.2 mg synthesized mol-
ecules in 1000 µL acetonitrile/0.1% TFA (1:1, v/v). The clear sample solutions were 
pipetted onto the MALDI target plate (MTP 384 target plate, massive steel, Bruker 
Daltonics) After crystallization the mass spectra were acquired with an Autoflex 
II MALDI TOF/TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) 
equipped with a 337-nm pulsed nitrogen laser (MNL-205MC; LTB Lasertechnik 
Berlin, Berlin, Germany). MALDI measurements were performed in reflectron 
mode in a detection range of m/z 120 to 1000. Ions were accelerated under delayed 
extraction conditions (120 ns) in positive and in negative ion modes with an accel-
eration voltage of 20.00 kV. We used alpha-cyano-4-hydroxycinnamic acid (CHCA) 
matrix peaks as external calibration. The instrument was controlled and data was 
processed using FlexControl 2.4 and FlexAnalysis 3.4 software packages (Bruker 
Daltonics, Bremen, Germany.)
CD: CD and UV measurements were performed on a Jasco J-720 spectropola-
rimeter (Jasco Ltd., Tokyo, Japan) in Jasco cylindrical cuvettes with path length 
of 10 mm. One milligram of chicken erythrocyte DNA (Reanal, Budapest, Hun-
gary) was dissolved in 10  mL distilled water (stock solution, 0.1  mg/mL) and 
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was further diluted to 0.033 mg/mL for the experiments. Tested substances were 
dissolved in DMSO (Sigma-Aldrich, Budapest, Hungary) in 5–10 mM concentra-
tion. All experiments were performed at ambient temperature.
General method for the synthesis of compounds 6f, 6g, 6h, 6m, 6o, 6p (Method A: 
acid‑catalyzed Claisen‑Schmidt condensation)
A solution of 0.1  mol (1.141  g) 4-hydroxycyclohexanone and 0.2  mol of the 
appropriate arylaldehyde in 15 mL of glacial acetic acid was treated with 4 drops 
of concentrated sulfuric acid. This mixture was left to stand at room temperature 
until the starting materials couldn’t be detected on the TLC plate. The reaction 
mixture was then diluted with 100  mL water. After 10  min stirring the yellow 
solid was collected on a glass filter, treated with 25 ml of 5% aqueous solution of 
potassium hydrogencarbonate and washed with water. The yellow solid was dried 
and recrystallized from a suitable solvent.
(2E,6E)‑2,6‑Bis(4′‑nitrobenzylidene)‑4‑hydroxycyclohexanone (6f) Overall yield: 85%. 
Mp: 216–218 °C (MeOH/CHCl3); Lit.: 210–213 °C [42]. 1H-NMR (500 MHz,  CDCl3) 
δ (ppm) 3.06–3.18 (br m, 4H), 5.21 (m, 1H), 7.59 (d, J = 9.0 Hz, 4H), 7.92 (s, 2H), 8.29 
(d, J = 9.0 Hz, 4H). 13C-NMR (125 MHz,  CDCl3) δ (ppm) 32.9, 66.9, 123.8, 130.7, 
134.1, 137.4, 141.4, 147.6, 187.2. MS: m/z calculated for  C20H16N2O6: see Table 1.
(2E,6E)‑2,6‑Bis(2′‑nitrobenzylidene)‑4‑hydroxycyclohexanone (6g) Overall yield: 81%. 
Mp: 178–179  °C (MeOH/CHCl3). 1H-NMR (500  MHz, DMSO-D6) δ (ppm) 2.84 
(m, 2H), 2.95 (m, 2H), 4.97 (s, 1H), 7.54 (d, J = 7.5 Hz, 2H), 7.68 (t, J = 7.9 Hz, 2H), 
7.83 (t, J = 7.5 Hz, 2H), 7.93 (s, 2H), 8.19 (d, J = 7.9 Hz, 2H). 13C-NMR (125 MHz, 
DMSO-D6) δ (ppm) 31.4, 67.2, 124.8, 129.8, 130.5, 130.9, 133.2, 133.8, 135.5, 147.7, 
186.6. MS: m/z calculated for  C20H16N2O6: see Table 1.
(2E,6E)‑2,6‑Bis(3′‑nitrobenzylidene)‑4‑hydroxycyclohexanone (6h) Overall yield: 79%. 
Mp: 168–169  °C (MeOH/CHCl3). 1H-NMR (500  MHz, acetone-D6) δ (ppm) 3.29 
(m, 2H), 3.35 (m, 2H), 5.27 (m, 1H), 7.79 (t, J = 8.0 Hz, 2H), 7.90 (s, 2H), 7.99 (d, 
J = 8.0 Hz, 2H), 8.27 (d, J = 8.0 Hz, 2H), 8.36 (s, 2H). 13C-NMR (125 MHz, acetone-
D6) δ (ppm) 34.2, 69.0, 125.2, 126.2, 126.6, 131.9, 136.4, 137.8, 137.9, 139.0, 188.6. 
MS: m/z calculated for  C20H16N2O6: see Table 1.
(2E,6E)‑2,6‑Bis(4′ ‑hydroxy‑3′ ‑methoxybenzylidene)‑4‑hydroxycyclohexanone 
(6m) Overall yield: 86%. Mp: 217–218 °C (MeOH). 1H-NMR (500 MHz, DMSO-
D6) δ (ppm) 2.89 (m, 2H), 3.06 (m, 2H), 3.81 (s, 6H), 3.98 (s, 1H), 6.86 (m, 2H), 
7.03 (m, 2H), 7.11 (s, 2H), 7.60 (s, 2H). 13C-NMR (125 MHz, DMSO-D6) δ (ppm) 
36.6, 56.2, 64.2, 115.3, 116.0, 124.5, 127.4, 131.4, 137.8, 147.9, 148.3, 188.3. MS: 
m/z calculated for  C22H22O6: see Table 1.
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(2E,6E)‑2,6‑Bis[(3′‑pyridinyl)methylene]‑4‑hydroxycyclohexanone (6o) Overall yield: 
77%. Mp: 198–199 °C (MeOH). 1H-NMR (500 MHz, DMSO-D6) δ (ppm) 2.94 (m, 
2H), 2.98 (m, 2H), 4.08 (s, 1H), 4.97 (m, 1H), 7.49 (m, 2H), 7.68 (s, 2H), 7.96 (m, 
2H), 8.57 (m, 2H), 8.74 (s, 2H). 13C-NMR (125 MHz, DMSO-D6) δ (ppm) 35.5, 
62.8, 123.5, 131.1, 133.7, 135.5, 136.8, 149.2, 150.9, 187.8. MS: m/z calculated for 
 C18H16N2O2: see Table 1.
(2E,6E)‑2,6‑Bis[(4′‑pyridinyl)methylene]‑4‑hydroxycyclohexanone (6p) Overall yield: 
82%. Mp: 212–213 °C (MeOH). 1H-NMR (500 MHz, DMSO-D6) δ (ppm) 2.96 (m, 
2H), 2.99 (m, 2H), 4.10 (m, 1H), 5.01 (m, 1H), 7.49 (d, J = 5.9 Hz, 4H), 7.59 (s, 2H), 
8.65 (d, J = 5.9 Hz, 4H). 13C-NMR (125 MHz, DMSO-D6) δ (ppm) 35.3, 39.4, 62.5, 
124.0, 134.3, 137.2, 142.4, 149.8, 188.1. MS: m/z calculated for  C18H16N2O2: see 
Table 1.
Table 1  MALDI-TOF MS data of the newly synthesized compounds. The presence of [M-H]+ ions 
proves the hydride transfer, the [M + H]+ the proton transfer mechanism of fragmentation in positive 
mode
Compound [M-H]+ [M + H]+ [M]+
Calculated Observed Calculated Observed Calculated Observed
6a 289.123 289.127 291.139 291.172 290.131 290.126
6b 357.046 357.030 359.061 359.030 358.053 358.030
6c 424.967 424.950 426.983 426.953 425.975 426.953
6d 357.046 357.059 359.061 359.060 358.053 358.026
6e 357.061 357.036 359.061 359.036 358.053 358.034
6f 379.093 379.086 381.109 381.025 380.101 380.119
6g 379.093 379.865 381.109 381.955 380.101 380.117
6h 379.093 379.149 381.109 381.115 380.101 380.155
6i 375.207 375.200 378.264 377.256 376.215 376.252
6j 349.144 349.146 351.160 351.163 350.152 350.154
6k 409.137 409.135 411.181 411.145 410.173 410.145
6l 349.144 349.171 351.160 351.176 350.152 350.179
6m 381.134 381.138 383.150 383.155 382.142 382.094
6n 317.154 317.187 319.170 319.209 318.162 318.196
6o 291.113 291.161 293.129 293.179 292.121 292.168
6p 291.113 291.089 293.129 293.138 292.121 292.115
6q 341.154 341.158 343.170 343.154 342.162 342.169
15 633.228 633.015 635.244 635.201 634.236 634.061
18a 350.095 350.160 352.111 352.162 351.103 351.106
18b 418.017 418.018 420.033 420.024 419.025 419.020
18c 410.116 410.126 412.132 412.127 411.124 411.124
18d 436.179 436.149 438.195 438.182 437.187 437.158
19 365.094 365.144 367.110 367.148 366.102 366.146
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General method for the synthesis of compounds 6a, 6b, 6c, 6d, 6e, 6i, 6j, 6k, 6l, 6n, 
6q (Method B: base‑catalyzed Claisen‑Schmidt condensation)
A solution of 0.1  mol (1.141  g) 4-hydroxycyclohexanone and 0.2  mol of the 
appropriate arylaldehyde in 20  mL of methanol was treated with a solution of 
0.3  mol (1.683  g) potassium hydroxide in 20  mL of water. This mixture was 
stirred at room temperature on a magnetic stirrer until the starting materials 
couldn’t be detected on the TLC plate from the mother liquor. The reaction mix-
ture was then diluted with 100 mL water. The precipitated yellow solid was col-
lected on a glass filter and washed with water. The yellow solid was dried, and 
recrystallized from a suitable solvent.
(2E,6E)‑2,6‑Bis(benzylidene)‑4‑hydroxycyclohexanone (6a) Overall yield: 88%. Mp: 
139–140  °C (MeOH). 1H-NMR (500  MHz,  CDCl3) δ (ppm) 1.94 (s, 1H), 2.98 
(m, 2H), 3.19 (m, 2H), 4.12 (m, 1H), 7.45 (br m, 10H), 7.88 (s, 2H). 13C-NMR 
(125  MHz,  CDCl3) δ (ppm) 36.5, 65.6, 128.4, 128.8, 130.3, 132.3, 135.5, 139.3, 
188.8. MS: m/z calculated for  C20H18O2: see Table 1.
(2E,6E)‑2,6‑Bis(4′‑chlorobenzylidene)‑4‑hydroxycyclohexanone (6b) Overall yield: 
86%. Mp: 167–168  °C (MeOH). 1H-NMR (500  MHz,  CDCl3) δ (ppm) 2.97 (dd, 
J = 1.7, 7.8 Hz, 1H), 3.00 (dd, J = 1.7, 7.8 Hz, 1H), 3.14 (s, 1H), 3.17 (s, 1H), 4.18 
(m, 1H), 7.38 (s, 8H), 7.82 (s, 2H). 13C-NMR (125  MHz,  CDCl3) δ (ppm) 36.4, 
65.4, 128.8, 131.5, 132.6, 133.9, 135.0, 138.1, 188.3. MS: m/z calculated for 
 C20H16Cl2O2: see Table 1.
(2E,6E)‑2,6‑Bis(2′,4′‑dichlorobenzylidene)‑4‑hydroxycyclohexanone (6c) Overall 
yield: 82%. Mp: 180–182 °C (MeOH/CHCl3). 1H-NMR (500 MHz, DMSO-D6) δ 
(ppm) 2.81 (m, 2H), 2.92 (m, 2H), 4.00 (m, 1H), 4.96 (s, 1H), 7.53 (br m, 4H), 
7.71 (s, 2H), 7.76 (s, 2H). 13C-NMR (125  MHz, DMSO-D6) δ (ppm) 35.3, 63.1, 
127.2, 129.1, 131.8, 132.3, 132.7, 133.9, 134.8, 136.0, 187.6. MS: m/z calculated for 
 C20H14Cl4O2: see Table 1.
(2E,6E)‑2,6‑Bis(3′‑chlorobenzylidene)‑4‑hydroxycyclohexanone (6d) Overall yield: 
85%. Mp: 120–122  °C (EtOH). 1H-NMR (500  MHz,  CDCl3) δ (ppm) 2.99 (d, 
J = 7.6 Hz, 1H), 3.02 (d, J = 7.6 Hz, 1H), 3.14 (s, 1H), 3.17 (s, 1H), 4.19 (m, 1H), 
7.32 (br m, 6H), 7.41 (s, 2H), 7.80 (s, 2H). 13C-NMR (125 MHz,  CDCl3) δ (ppm) 
36.3, 65.3, 128.4, 128.9, 129.7, 129.8, 133.2, 134.4, 137.2, 138.0, 188.2. MS: m/z 
calculated for  C20H16Cl2O2: see Table 1.
(2E,6E)‑2,6‑Bis(2′‑chlorobenzylidene)‑4‑hydroxycyclohexanone (6e) Overall yield: 
80%. Mp: 152–153  °C (MeOH). 1H-NMR (500  MHz,  CDCl3) δ (ppm) 2.85 (m, 
2H), 3.02 (m, 2H), 4.11 (m, 1H), 7.26–7.32 (br m, 6H), 7.44 (m, 2H), 8.02 (s, 2H). 
13C-NMR (125 MHz,  CDCl3) δ (ppm) 36.5, 65.9, 126.4, 129.8, 129.9, 130.3, 134.0, 
134.1, 135.0, 136.7, 188.1. MS: m/z calculated for  C20H16Cl2O2: see Table 1.
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(2E,6E)‑2,6‑Bis(4′‑dimethylaminobenzylidene)‑4‑hydroxycyclohexanone (6i) Overall 
yield: 78%. Mp: 264–265 °C (MeOH/CHCl3). 1H-NMR (500 MHz, DMSO-D6) δ 
(ppm) 2.83 (m, 2H), 2.98 (s, 12H), 3.07 (m, 2H), 3.92 (s, 1H), 4.91 (s, 1H), 6.77 (d, 
J = 8.3 Hz, 4H), 7.41 (d, J = 8.3 Hz, 4H), 7.56 (s, 2H). 13C-NMR (125 MHz, DMSO-
D6) δ (ppm) 36.5, 56.3, 64.0, 111.6, 122.9, 129.0, 132.0, 137.1, 150.3, 187.2. MS: 
m/z calculated for  C24H28N2O2: see Table 1.
(2E,6E)‑2,6‑Bis(4′‑methoxybenzylidene)‑4‑hydroxycyclohexanone (6j) Overall yield: 
81%. Mp: 162–163 °C (MeOH/CHCl3). 1H-NMR (500 MHz,  CDCl3) δ (ppm) 2.96 
(dd J = 1.6, 8.4 Hz, 1H), 2.99 (dd J = 1.6, 8.4 Hz, 1H), 3.21 (d, J = 3.0 Hz, 1H), 3.24 
(d, J = 3.0 Hz, 1H), 3.84 (s, 6H), 4.14 (m, 1H), 6.93 (d, J = 8.7 Hz, 4H), 7.44 (d, 
J = 8.7 Hz, 4H), 7.85 (s, 2H). 13C-NMR (125 MHz,  CDCl3) δ (ppm) 36.7, 55.3, 66.0, 
114.0, 128.3, 130.4, 132.2, 138.9, 160.2, 188.6. MS: m/z calculated for  C22H22O4: 
see Table 1.
(2E,6E)‑2,6‑Bis(3′,4′‑dimethoxybenzylidene)‑4‑hydroxycyclohexanone (6k) Overall yield: 
82%. Mp: 158–159 °C (MeOH). 1H-NMR (500 MHz,  CDCl3) δ (ppm)2.99 (dd, J = 1.6, 
8.2 Hz, 1H), 3.02 (dd, J = 1.6, 8.2 Hz, 1H), 3.21 (d, J = 2.4 Hz, 1H), 3.24 (d, J = 2.4 Hz, 
1H), 3.90 (s, 6H), 3.91 (s, 6H), 4.17 (m, 1H), 6.92 (d, J = 8.4 Hz, 2H), 6.99 (d, J = 1.6 Hz, 
2H), 7.09 (dd, J = 1.6, 8.4 Hz, 2H), 7.83 (s, 2H). 13C-NMR (125 MHz,  CDCl3) δ (ppm) 
36.7, 55.9, 56.0, 65.8, 111.0, 113.8, 123.9, 128.5, 130.6, 139.2, 148.7, 149.9, 188.5. MS: 
m/z calculated for  C24H26O6: see Table 1.
(2E,6E)‑2,6‑Bis(3′‑methoxybenzylidene)‑4‑hydroxycyclohexanone (6l) Overall yield: 
82%. Mp: 95–96 °C (MeOH). 1H-NMR (500 MHz,  CDCl3) δ (ppm) 3.01 (m, 2H), 
3.20 (m, 2H), 3.83 (s, 6H), 4.15 (m, 1H), 6.91 (d, J = 8.2  Hz, 2H), 6.97 (s, 2H), 
7.04 (d, J = 8.2 Hz, 2H), 7.32 (m, 2H), 7.85 (s, 2H). 13C-NMR (125 MHz,  CDCl3) 
δ (ppm) 36.5, 55.3, 65.7, 114.5, 115.7, 122.7, 129.4, 132.6, 136.9, 139.3, 159.5, 
188.7. MS: m/z calculated for  C22H22O4: see Table 1.
(2E,6E)‑2,6‑Bis(4′‑methylbenzylidene)‑4‑hydroxycyclohexanone (6n) Overall yield: 
86%. Mp: 155–156 °C (MeOH). 1H-NMR (500 MHz, DMSO-D6) δ (ppm) 2.34 (s, 
6H), 2.91 (m, 2H), 3.05 (m, 2H), 3.99 (m, 1H), 4.93 (m, 1H), 7.28 (d, J = 8.0 Hz, 
4H), 7.43 (d, J = 8.0  Hz, 4H), 7.63 (s, 2H). 13C-NMR (125  MHz, DMSO-D6) δ 
(ppm) 20.9, 35.9, 63.3, 129.1, 130.2, 132.5, 132.9, 138.8, 138.5, 188.1. MS: m/z 
calculated for  C22H22O2: see Table 1.
(2E,6E)‑2,6‑Bis(cinnamylidene)‑4‑hydroxycyclohexanone (6q) Overall yield: 87%. 
Mp: 195–196 °C (MeOH/CHCl3). 1H-NMR (500 MHz,  CDCl3) δ (ppm) 2.87 (m, 
2H), 3.11 (m, 2H), 4.28 (m, 1H), 7.05 (br m, 4H), 7.31 (m, 2H), 7.36 (m, 4H), 7.50 
(m, 4H), 7.56 (m, 2H). 13C-NMR (125  MHz,  CDCl3) δ (ppm) 35.2, 65.7, 123.3, 
127.3, 128.8, 129.0, 131.6, 136.6, 138.6, 141.7, 187.3. MS: m/z calculated for 
 C24H22O2: see Table 1.
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General method for the synthesis of compounds 18a–d and 19
The appropriate bis(benzylidene)-cyclanone 17a–d or 6a (2 mmol) was dissolved 
in a warm (50–60 °C) solution of 35 mL dry toluene and triethylamine (2 mmol, 
0.202  g). After removal of heating 2  mmol (0.226  g) chloroacetyl chloride in 
10 ml of dry toluene was added dropwise to the above solution in 30 min under 
continuous stirring. Magnetic stirring was continued until the disappearance of 
the starting materials from the TLC plate. The mixture was evaporated to dry-
ness under reduced pressure. The residue was triturated with 50 mL water and the 
precipitated yellow solid filtered off. After washing the solid several times with 
water the crystals were dried and recrystallized from a suitable solvent.
1‑(α‑Chloroacetyl)‑(3E,5E)‑3,5‑bis(benzylidene)‑piperidin‑4‑one (18a) Prepared from 
(3E,5E)-3,5-bis(benzylidene)-piperidin-4-one (17a) [28]. Overall yield: 83%. Mp: 
145–146 °C (toluene). 1H-NMR (500 MHz,  CDCl3) δ (ppm) 3.88 (s, 2H), 4.78 (s, 
2H), 4.91 (s, 2H), 7.40 (br m, 10H), 7.84 (s, 1H), 7.89 (s, 1H). 13C-NMR (125 MHz, 
 CDCl3) δ (ppm) 40.6, 43.9, 46.7, 128.7, 128.9, 129.6, 129.7, 130.0, 130.5, 130.9, 
134.2, 134.3, 137.8, 138.8, 165.2, 185.9. MS: m/z calculated for  C21H18ClNO2: see 
Table 1.
1‑(α‑Chloroacetyl)‑(3E,5E)‑3,5‑bis(4′‑chlorobenzylidene)‑piperidin‑4‑one (18b) Pre-
pared from (3E,5E)-3,5-bis(4′-chlorobenzylidene)-piperidin-4-one (17b) [28]. Over-
all yield: 81%. Mp: 169–170 °C (EtOH). 1H-NMR (500 MHz,  CDCl3) δ (ppm) 3.91 
(s, 2H), 4.77 (s, 2H), 4.88 (s, 2H), 7.28–7.48 (br m, 8H), 7.79 (s, 1H), 7.83 (s, 1H). 
13C-NMR (125 MHz,  CDCl3) δ (ppm) 40.6, 43.8, 46.9, 129.2, 129.3, 131.2, 131.3, 
131.7, 132.7, 132.8, 136.0, 136.1, 136.8, 137.7, 165.2, 185.5. MS: m/z calculated for 
 C21H16Cl3NO2: see Table 1.
1‑(α‑Chloroacetyl)‑(3E,5E)‑3,5‑bis(4′‑methoxybenzylidene)‑piperidin‑4‑one (18c) Pre-
pared from (3E,5E)-3,5-bis(4′-methoxybenzylidene)-piperidin-4-one (17c) [28]. 
Overall yield: 80%. Mp: 162–163 °C (MeOH). 1H-NMR (500 MHz,  CDCl3) δ (ppm) 
3.82 (s, 6H), 3.92 (s, 2H), 4.75 (s, 2H), 4.88 (s, 2H), 6.93 (d, J = 7.9 Hz, 2H), 6.96 
(d, J = 7.9 Hz, 2H), 7.33 (d, J = 7.9 Hz, 2H), 7.41 (d, J = 7.9 Hz, 2H), 7,77 (s, 1H), 
7.80 (s, 1H). 13C-NMR (125 MHz,  CDCl3) δ (ppm) 40.9, 44.1, 47.0, 55.4, 114.4, 
114.5, 127.0, 127.3, 128.9, 129.1, 132.2, 132.7, 137.4, 138.4, 160.9, 165.2, 185.8. 
MS: m/z calculated for  C23H22ClNO4: see Table 1.
1‑(α‑Chloroacetyl)‑(3E,5E)‑3,5‑bis(4′‑dimethylaminobenzylidene)‑piperidin‑4‑one 
(18d) Prepared from (3E,5E)-3,5-bis(4′-dimethylaminobenzylidene)-piperidin-4-
one (17d) [28]. Overall yield: 85%. Mp: 223–224 °C (EtOH). 1H-NMR (500 MHz, 
 CDCl3) δ (ppm) 3.05 (m, 6H), 3.97 (s, 2H), 4.80 (s, 2H), 4.94 (s, 2H), 6.72 (m, 
4H), 7.34 (m, 2H), 7.42 (m, 2H), 7.78 (s, 1H), 7.81 (s, 1H). 13C-NMR (125 MHz, 
 CDCl3) δ (ppm) 40.0, 41.0, 44.3, 47.1, 111.9, 122.3, 122.8, 126.6, 126.9, 132.4, 
133.0, 137.7, 138.8, 151.0, 165.2, 185.7. MS: m/z calculated for  C25H28ClN3O2: see 
Table 1.
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(2E,6E)‑2,6‑Bis(benzylidene)‑4‑(α‑chloroacetoxy)‑cyclohexanone (19) Prepared from 
(2E,6E)-2,6-bis(benzylidene)-cyclohexan-4-one (6a). Overall yield: 85%. Mp: 159–
160 °C (MeOH). 1H-NMR (500 MHz,  CDCl3) δ (ppm) 3.22 (m, 4H), 3.97 (s, 2H), 
5.31 (m, 1H), 7.35–7.47 (br m, 10 H), 7.94 (s, 2H). 13C-NMR (125 MHz,  CDCl3) δ 
(ppm) 32.8, 40.8, 69.7, 128.6, 129.1, 130.2, 130.8, 135.2, 140.0, 166.6, 187.8. MS: 
m/z calculated for  C22H19ClO3: see Table 1.
General method for the synthesis of compounds 15 and 16
Oxaloyl chloride (2.5 mmol) was added to a stirred suspension of 5 mmol of the cor-
responding bis(benzylidene)cyclanone and 50 mL of dry toluene containing 5 mmol 
triethylamine at roughly 20 °C. The reaction mixture was stirred and left overnight 
at room temperature. Then this the mixture was diluted with 50 mL of water. The 
precipitated yellow solid was collected on a glass filter, washed thoroughly with 
water, dried and recrystallized from methanol.
1,2‑Bis[(2E,6E)‑2,6‑bis(benzylidene)‑4‑oxycyclohexanone‑4‑yl]ethane‑1,2‑dione 
(15) Prepared from compound 6a. Overall yield: 85%. Mp: 247–248 °C (MeOH). 
1H-NMR (500  MHz,  CDCl3) δ (ppm) 3.17 (m, 4H), 3.30 (m, 4H), 5.24 (s, 2H), 
7.30–7.49 (br m, 20H), 7.93 (s, 4H). 13C-NMR (125 MHz,  CDCl3) δ (ppm) 32.7, 
71.4, 128.6, 129.1, 130.2, 130.5, 135.1, 140.2, 156.6, 187.4. MS: m/z calculated for 
 C42H34O6: see Table 1.
1,2‑Bis[(3E,5E)‑3,5‑bis(benzylidene)‑4‑piperidon‑1‑yl]ethane‑1,2‑dione (16) Prepared 
from (3E,5E)-3,5-bis(benzylidene)-piperidin-4-one (17a) [28]. Overall yield: 88%. 
Mp: 243–244 °C; Lit.: 245–246 °C [18].
2,4‑Dimethyl‑1,5‑diphenylpenta‑1,4‑dien‑3‑one (2e) (4) This compound was prepared 
according to a known method [45]. Overall yield: 40%. Mp: 125–127 °C; Lit.: 127–
128 °C [45].
1‑Methyl‑(3E,5E)‑3,5‑bis(benzylidene)‑4‑piperidone (5a) and 1‑Methyl‑(3E,5E)‑3,5‑bis(4
′‑chlorobenzylidene)‑4‑piperidone (5b) These compounds were prepared according 
to a known method [28]. Mp: 5a –  116–117 °C; Lit.: 116–117 °C [28]. 5b – 183–
184 °C; Lit.: 184–185 °C [28].
(2E,6E)‑2,6‑Bis(benzylidene)‑4‑methylcyclohexanone (7a) and (2E,6E)‑2,6‑Bis(4′‑ch
lorobenzylidene)‑4‑methylcyclohexanone (7b) These compounds were prepared 
according to a known methods [46] and [47], respectively. Mp: 7a – 98–99 °C; Lit.: 
98–99 °C [46]. 7b – 163–164 °C; Lit.: 156–160 °C [47].
Determination of antiproliferative action in vitro
The antiproliferative properties of the synthesized compounds were determined 
against a panel of human adherent cancer cell lines. Briefly, MDA-MB-231 (breast), 
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C33A (cervical) and A2780 (ovarian) cancer cell lines cell were purchased from 
European Collection of Cell Cultures (ECCAC, Salisbury, UK) and maintained 
in minimal essential medium (MEM) supplemented with 10% fetal bovine serum 
(FBS), 1% non-essential amino acids and an antibiotic–antimycotic mixture (Lonza 
Group Ltd., Basel, Switzerland). Near-confluent cancer cells were seeded onto a 
96-well microplate (5000/well) and after overnight standing new medium, contain-
ing the tested compounds at 0.3, 3 and 30 µM, was added. After incubation for 72 h 
at 37 °C in humidified air with 5%  CO2, the viability of the cells were determined 
by the addition of 20 µL of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) solution. The mitochondrial reductase of the intact cells 
metabolized the MTT and the produced formazan was precipitated as purple crys-
tals during a 4-h contact period. The formazan was dissolved in 100 µL of DMSO 
during a 60-min period of shaking at 37 °C assayed at 545 nm, using a microplate 
reader [50]. In the case of the most active compounds the assays were repeated with 
a set of dilutions (0.03–10 mM), concentration–response curves were fitted to the 
generated data and the  IC50 values were calculated by means of GraphPad Prism 4.0 
(GraphPad Software, San Diego, CA, USA). The experiments were carried out on 
two microplates with five parallel wells. Stock solutions of the tested compounds 
(10  mM) were prepared in DMSO. The highest DMSO content of the medium 
(0.3%) did not have any substantial effect on the cell proliferation. Cisplatin (Ebewe 
Pharma GmbH, Unterach, Austria) was used as a reference agent.
Physiscochemical calculations
For the prediction of some physicochemical parameters of our compounds we have 
used the Calculator Plugins of ChemAxon. The ClogP values were calculated with 
the Klopman method and database of the software. The ClogP,  pKa and solubility 
values are results at physiological pH = 7.4. See the corresponding homepage for 
detailed conditions of the calculations [43]. To explain the relationship between bio-
data and calculated physicochemical parameters the Lipinski approaches have been 
used [44].
Results and discussion
Design and synthesis
Our purpose is to give further insight into the influence of structural modifica-
tions at position 4 of the cyclic ketone scaffold on the biological effect. We proved 
among other things [28] that this position, being an auxiliary binding ability (sec-
ondary pharmacophore) to the in vivo biological site of action, has great influ-
ence on the cytotoxicity of these compounds. In other words, the binding strength 
of the  C5-curcuminoids to the biological site of action is weak when merely the 
pentadienone moiety reacts. The substituent at position 4 on the cyclanone ring is 
able to enhance the interaction between the  C5-curcuminoids and their biological 
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place of action in the cancer cell. Therefore, we set out to synthesize compounds 
4–7 for comparative structure–activity relationship (Fig. 2) investigation.
Syntheses of compounds in series 5–7 and 15–19 are outlined in Schemes 1, 
2, 3 and 4. Briefly, compound 4 and the bis(arylidene)-cyclanones 5–7 were syn-
thesized via acid- or base-catalyzed condensation of diethylketone, 4-hydroxy-
cyclohexanone, 4-methylcyclohexanone or 4-piperidone hydrochloride with aryl 
aldehydes according to the Claisen-Schmidt condensation protocol [28].
Another objective was the synthesis of a new branch of cyclic  C5-curcuminoid 
with a hydroxyl functionality at position 4 (6) and derivatives of series 6 with 
different aryl substituents (Schemes 1,2, 4.) to receive data on the impact of the 
corresponding structural changes on cytotoxicity.
The optimal para substituents (H, Cl,  OCH3,  NO2, OH, dimethylamino) on the 
arylidene moiety was selected according to a previous disclosure on this substitu-
ent effect [29]. “Optimal” means that the chosen substituents on the arylidene 
group have different electronic, hydrophobic and steric properties fitting well to 
Craig plot for para substituents assuring the divergence of the σp and π values 
[30, 31]. Special aromatic aldehydes like pyridincarbaldehyde and cinnamalde-
hyde were also used (Scheme 2).
The synthesis of the dimeric compound 15 was performed by acylation of the 
monomer 6a with oxaloyl chloride in the presence of triethylamine analogously 
to compound 16, which was prepared by others earlier [18] (Scheme 3).
Chloroacetyl derivatives 18 and 19 were obtained from their corresponding 
dibenzylidene precursors 6a and 17a–d with chloroacetyl chloride in the presence 
of trimethylamine (Scheme 4).
Fig. 2  Acyclic (4) and cyclic (5–7)  C5-curcuminoids
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Structural characterization of the title compounds
Structures of the compounds synthesized were established by means of 1H, 13C 
NMR and MS measurements. The NMR spectra of compounds in series 6 were 
similar and simple in appearance. The E,E-configuration of the newly synthesized 
compounds was determined by 1H NMR [32]. The E,E-configuration is due to the 
Scheme 1  The synthesis of series 6 from 4-hydroxycyclohexanone and aromatic aldehydes. Compound 
12 was prepared according to a known method [38]
Scheme 2  The synthesis of derivatives 6o-q 
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anisotropic effect of the carbonyl group on the vinyl protons, which is not possi-
ble in the Z,Z-configurational forms.
Our research group is using, among others, matrix-assisted laser desorption ioni-
zation (MALDI) technique for single-stage MS analysis. Because of its large mass 
range, the device is a time-of-flight spectrometer (MALDI-TOF). This technique 
Scheme 3  The synthesis of the diester derivative 15 
Scheme 4  The synthesis of chloroacetyl derivatives 18 and 19 
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was used also in our previous study on cyclic  C5-curcuminoids [28]. We have inves-
tigated a number of analytes in the series of 3,5-dibenzylidene-4-piperidones and 
2,6-dibenzylidene-1-cyclanones. All compounds showed characteristic molecular 
ion peaks (Table 1). In general we can state that the diagnostic product ions were not 
only fragments, but also dimers or sometimes trimers of the molecular ions in their 
MS spectra. The dimerization is a common photochemical [2 + 2] cycloaddition. 
The photodimerisation, as a type of autodimerization, is well-known in this family 
of compounds [33–36]. The reaction proceeds via a stepwise sequence. The product 
is a dispiro cyclobutane derivative in general, as is compound 20 in our case. We 
have selected compound 6a to demonstrate what happens due to our general opinion 
(Scheme 5) regardless of the type of the central cyclanone core in the structure.
Mention must be made about the fact that it was not necessary to use a matrix. 
These curcuminoids are able to ionize themselves. They can behave as their own 
matrix in the presence of the laser shots.
There is a recent report on the unexpected formation of [M-H]+ ion dur-
ing MALDI MS analysis of such cyclic  C5-curcuminoids [37]. This ion can form 
under chemical experimental conditions [33–36] in the photochemical reaction too, 
together with the [M + H]− ion in a hydride transfer reaction. Therefore, it is not a 
surprise that the dimerization (2 + 2 cycloaddition) takes place. A very similar reac-
tion is observable if we look at the proton transfer reaction. These two processes, 
hydride and/or proton transfer makes the cycloaddition possible. The molecular ion 
of dimeric compound 20 (or the dimeric fragment after loss of Cl or  NO2 in the case 
of derivatives 18 or 6f) is there in the MALDI-TOF MS spectra of 6a. Similarly, all 
the product ions in Scheme 5 are there in the corresponding negative or positive ion 
mode records. The analytically useful diagnostic product ions are of importance for 
example when we analyze samples from complex biological matrices for identity or 
quantity of these  C5-curcuminoids. That is why we propose to consider the dimeric 
ion or its fragment too for the mass spectrometric fingerprint analysis of these 
 C5-curcuminoids in a MALDI-TOF technique for the future biological research.
Antiproliferative effects in vitro
The primary objective of the present work stems from our interest to study 
structure–activity relationships concerning these antiproliferative synthetic 
 C5-curcuminoids. The biodata presented in Fig.  3 reveals that the majority of the 
newly described  C5-curcuminiod derivatives exert pronounced antiproliferative 
activities as evaluated against the following three human adherent cancer cell lines: 
A2780 (ovarian), C33A (cervix) and MDA-MB-231 (breast). Data in Fig. 3 indicate 
the percentage of cell-growth-inhibition of the different cell lines in three different 
concentrations (0.3 μM, 3 μM and 30 μM) of the corresponding compound.
Comparisons were made between the cytotoxic properties of compounds 4–7 
(Fig. 2). Firstly, we can see a clear sequence among the structures in Fig. 2 regard-
ing their activity. The heterocyclic derivatives 5a and 5b dominates the others in 
the case of all three cell lines. The second position is shared by the two homocyclic 
derivatives 6 and 7 favoring the hydroxyl-substituted compounds 6a and 6b in the 
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Scheme 5  The formation of dimer 20 from 6a under MALDI-TOF conditions (see experimental) in MS 
analysis. The related product ions of 6a observed: 289.127/[M-H]+; 291.172/[M + H]+; 290.126/[M] 
and the dimer 577.124/[M-3H]+; 580.119 [M]. In negative mode: 289.062/[M-H]−; 291.176/[M + H]−; 
290.120/[M]
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case of the C33A (cervix) and A2780 (ovarian) cancer cells. The inhibition activ-
ity of the acyclic compound 4 in these two concentrations is negligible. Hence, the 
structural modifications in the ketone core of compounds 4–7 presented in Fig.  2 
provided the following sequence in cell-growth-inhibition: N-methylpiperidones 
(5a, b) > 4-hydroxycyclohexanones (6a, b) > 4-methylcyclohexanones (7a, b) > acy-
clic ketone (4).
On the other hand, there is also a sequence in the structure–activity relation of 
the different aromatic substituents in series 6. There is a hydroxyl substituent in all 
the structures at position 4 of the newly synthesized 2,6-dibenzylidene-4-hydroxy-
cyclohexanone 6a-m derivatives. The most active compounds are the nitro-substi-
tuted 6f (para), 6g (ortho) and 6h (meta) derivatives with nearly 100% inhibition 
in almost all cases even at 3  μM. The meta-nitro 6h counterpart shows the high-
est score, the other two isomers 6f and 6g are slightly weaker on C33A (cervix) 
cells. The second in this sequence is the pyridylidene substituent in derivatives 6o 
and 6p with better inhibition of the 4′-pyridyl derivative 6p on all three cell lines. 
The third position is occupied by the chloro substituent in compounds 6b (para), 6c 
(ortho,para–dichloro), 6d (meta) and 6e (ortho). The chloro-substituted subgroup 
is pharmacologically dominated by the meta-chloro 6d isomer with close to 100% 
inhibition on all cell lines. Interestingly, two of the most active cytotoxic derivative 
6d and 6h has an electron-withdrawing meta-substituent in its structure. Their calcu-
lated  IC50 values are as follows (see also Table 2): 6d: 2.46 (A2780), 1.38 (C33A), 
1.71 (MDA-MB-231); 6h: 0.68 (A2780), 0.69 (C33A), 0.92 (MDA-MB-231).
Unexpectedly, the replacement of the previously mentioned substituents to meth-
oxy group(s) in case of compounds 6j-m led to a lower inhibition percentage. These 
derivatives showed substancial inhibition only in the 30 μM concentration in almost 
all cases. Finally, the replacement of the para substituent on the aromatic rings by 
dimethylamino (6i), methyl (6n) or the exchange of the benzylidene groups to a 
longer aromatic obtained from cinnamaldehyde (6q), respectively, resulted in virtu-
ally inactive compounds. With the increase of the number of double bonds and the 
length of the spacer (from  C5 up to  C9) between the two aromatic rings in the struc-
ture of 6q the antiproliferative activity dropped to negligible.
These observations reveal that the electronic, hydrophobic and steric properties 
of the aryl substituents influence the magnitude of the inhibition ability of the com-
pounds. The relative potencies of the most active compounds in series 6 with respect 
of the substituents on the aryl rings is meta-NO2 (6h) > 4′-pyridyl (6p) > meta-Cl 
(6d) > ortho-NO2 (6g) > para-NO2 (6f) > 3′-pyridyl (6o) > hydrogen (6a). Some 
selected  IC50 calculated values (see also Table 2) - 6d: 2.46 (A2780), 1.38 (C33A), 
1.71 (MDA-MB-231); Average: 1.85. 6p: 0.76 (A2780), 2.69 (C33A), 1.28 (MDA-
MB-231); Average: 1.58. 6h: 0.68 (A2780), 0.69 (C33A), 0.92 (MDA-MB-231); 
Average: 0.76.
Only one of the members in series 6 was described earlier. Namely, compound 
6f has been identified as a potent nonselective isopeptidase inhibitor intermediate 
in vivo against glioblastoma U87MG cells [42].
Derivatives of compound 6a were also prepared in order to change the structure 
of the secondary pharmacophore [28] at position 4 of the molecules with what the 
molecule binds to its biological place of action. Two structural modifications were 
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accomplished on 6a: one of these acylation reactions provided the dimeric form 
15 (Scheme  3) while the other one the chloroacetyl derivative 19 (Scheme  4). It 
was possible to increase the efficacy of 6a with the introduction of the chloroacetyl 
moiety into the structure and inhibition ability grew dramatically from the 30 μM 
concentration of 6a down to the 0.3  μM of 19. The difference in inhibition abil-
ity of compounds 5 and 6 (Fig. 2) could have been equalized due to this transfor-
mation from 6a to 19 comparing biodata of chloroacetyl derivatives 18a–d and 19. 
The ester type compound 19, according to biodata in Fig.  3, reached the relative 
inhibition potential of the corresponding heterocyclic amide analogues 18a–d on all 
the three cell cultures. The difference in their inhibition activity can be seen in the 
0.3 μM concentration range, only (Fig. 3). The other attempt to modify the second-
ary binding part of 6a, however (Scheme 4), did not bring a positive change in anti-
proliferative action. The diester 15 proved to be less active compared to the analo-
gously synthesized [18] diamide 16.
An evaluation of the biodata was undertaken to see if there was any selectivity 
of the compounds on the different cell cultures. The results obtained from the  IC50 
calculations of representative compounds (see the footnotes in Fig. 3) in this inves-
tigation shows there are differences in inhibition ability on the three cell lines. For 
example, compound 6h inhibits the cell-proliferation very actively in both A2780 
and C33A, but it is less active in the case of MDA-MB-231 cells. Similarly, the most 
refractory cells against compound 6d were in the A2780 culture, and compound 6b 
showed the highest inhibition against the A2780 cell line. A similar tendency can be 
see among the derivatives with lower performances in the in vitro anticancer screen-
ing process. All in all, we can state there is a selectivity demonstrated by our com-
pounds on the different tumor cell lines.
The reference compound of this study was cisplatin. The best performer com-
pounds among the newly synthesized derivatives are 6d, 6p, 6h and 18c. Here we 
provide their calculated  IC50 values (see also Table  2): cisplatin = 1.30 (A2780); 
3.69 (C33A); 19.13 (MDA-MB-231); 6d = 2.46 (A2780), 1.38 (C33A), 1.71 (MDA-
MB-231); 6p = 0.76 (A2780), 2.69 (C33A), 1.28 (MDA-MB-231); 6h = 0.68 
(A2780), 0.69 (C33A), 0.92 (MDA-MB-231); 18c = 1.34 (A2780), 1.51 (C33A), 
1.00 (MDA-MB-231). In the case of the MDA-MB-231 cancer cell line, all the new 
compounds exceeded the antiproliferative effect of cisplatin, just as in the case of 
the C33A tumor cells. The ovarian A2780 cell line showed a similar effect in case of 
compound 18c, lower activity with compound 6d while increased cell growth inhi-
bition appeared in the case of 6p and 6h as compared to the reference compound.
Fig. 3  Evaluation of compounds 4–7, 15, 16, 18 and 19 against human A2780 (ovarian), C33A (cervix) 
and MDA-MB-231 (breast) cancer cell lines. The biodata reported here are percentage of cell-growth-
inhibition in different concentrations. Cisplatin was used as a reference drug:  IC50 = 1.30 (A2780); 3.69 
(C33A); 19.13 (MDA-MB-231). Some selected  IC50 calculated values (see also Table  2) = 6d: 2.46 
(A2780), 1.38 (C33A), 1.71 (MDA-MB-231); 6p: 0.76 (A2780), 2.69 (C33A), 1.28 (MDA-MB-231); 
6h: 0.68 (A2780), 0.69 (C33A), 0.92 (MDA-MB-231); 16 [18]: 0.22 (A2780), 0.43 (C33A), 0.37 (MDA-
MB-231); 18c: 1.34 (A2780), 1.51 (C33A), 1.00 (MDA-MB-231). There was only negligible inhibition 
noted in all cases of compounds in 0.3 μM concentration except for compounds 18 and 19. Inhibition 
data of curcumin: A2780, 85% in 30 μM [39]; C33A, 22% in 30 μM [40]; MDA-MB-231, 50% in 30 μM 
[41]
▸
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Inhibition percentage data of curcumin are known from the literature: A2780, 
85% in 30 μM [39]; C33A, 22% in 30 μM [40]; MDA-MB-231, 50% in 30 μM 
[41]. We can state, that the majority of the new compounds in series 6, 18 and 
derivative 15 and 19 are exceeding these values of curcumin. The compounds 
with lower antiproliferative activity are 6i, 6j and 6q in A2780 culture, 6i and 6q 
in C33A while 6i and 6q in MDA-MB-231.
DNA binding
CD is a reliable tool for the detection of DNA binding of ligands. The appearance 
of the induced circular dichroism signal (ICD) is definitive proof of the interac-
tion. In addition, shifts in the DNA bands are also indicative of the binding [48, 
49].
There is little known about the DNA binding of cyclic  C5-curcuminoids. About 
curcumin, however, we know more in this respect. It is known from in vitro experi-
ments, for example, that curcumin appears in the nucleus of cultured glioma cells 
after incubation. It was revealed that nuclear homing is not a result of curcumin’s 
DNA binding [27]. The temporal relationship of curcumin’s apoptotic induction 
effect and its nuclear homing is under investigation to acquire details about the 
mechanism of action. This fact among others prompted us to initiate measurements 
to see possible interactions between  C5-curcuminoids and DNA. For this reason, we 
conducted circular dichroism spectroscopic investigations on the newly synthesized 
cyclic  C5-curcuminoid derivatives in series 6 and 18 using natural DNA.
Curcumin, as well as 28  C5-curcuminoid derivatives were tested on chicken 
erythrocyte DNS. In the case of curcumin, a large ICD band appeared in the ligand’s 
absorption region, showing strong interaction between the molecule and the polynu-
cleotide (Fig. 4). It also caused some minor shift in the DNA band, meaning the dou-
ble helical structure is slightly distorted (Fig. 4). Out of the tested  C5-curcuminoid 
derivatives (6, 18), those containing either aliphatic or aromatic nitrogen showed 
signs of interaction—a weak ICD sign appeared in the recorded spectra for example 
in the case of 6i (Fig. 4). DNA bands did not change significantly in the same time, 
indicating that the polynucleotide remains in its native B-form. The binding is most 
probably the result of the ionic bondage of the nitrogen atoms in the ligand structure 
with the phosphate groups of DNA. In the case of other derivatives neither an ICD 
signal, nor shift in the DNA bands were detected, marking that no interaction occurs 
between the molecules (e.g. compounds 6h and 18c in Fig. 4).
Although it would be consistent with an ability of these curcuminoids to adopt 
a close-to-planar molecular shape, none of them showed stronger interaction with 
the DNA used in this study. It would be conceivable that the very active inhibi-
tor 6h or 18c show diverse interaction comparing to the practically ineffective 6i. 
However, compounds in series 6 and 18 showed similar properties under CD con-
ditions, that makes possible to generalize: based on these data we conclude that 
these derivatives do not bind to DNA in vitro. Hence, their antiproliferative effect 
is not due to their interaction with DNA.
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Physicochemical calculations on derivatives of series 6
For an evaluation of some physicochemical properties compared to curcumin the 
synthesized compounds were computed. ChemAxon’s Marvin Suite was used for all 
of the calculations [43].
The most promising compound from physicochemical point of view (Table 2) is 
the 4′-pyridylidene derivative 6p. This compound is one of those, which revealed 
the highest cytotoxic activity (6d, 6p, 6h and 18c) against the cancer cell lines, with 
a relatively low partition coefficient (ClogP), with the possibility for ionization and 
with the highest water-solubility. Its ionization is due to the presence of the two pyr-
idine nitrogen atoms which can be protonated under physiological conditions. The 
protonation can increase the solubility in water and decrease lypophilicity resulting 
in a possible better penetration through membranes into biological tissues, such as 
tumors. These data about this drug-candidate 6p are suggesting its possible higher 
bioavailability compared to curcumin consistent with Lipinski rules [44]. Similar 
physicochemical properties could be determined on the 3′-pyridylidene counterpart 
6o too.
In general, the molecular weight of the newly synthesized derivatives are in the 
range of that of curcumin except the highly chlorinated 6c, 18b, the methoxy or 
dimethylamino substituted 6k, 18c, 18d and the dimer 15. The calculated partition 
coefficient (ClogP) values are usually under 5 (in the majority of cases between 3 
and 4) or nearly 5 (6q, 18b, 19), except chlorinated compounds 6b-e and the para-
tolyl substituted 6n. The moderately active dimeric derivative 15 exhibited an 
extremely high ClogP value of 9.505.
Those compounds with a slightly basic nitrogen (6i, 6o, 6p and 18d) or with a 
phenolic OH group (6m) on the arylidene substituents are slightly less lypophilic 
than curcumin. The reason for this diminished lypophilicity can be protonation or 
deprotonation. The calculated water-solubility value, however, is increased only in 
the case of pyridylidene derivatives 6o and 6p. All of the compounds in Table  2 
are able to form 3–7 H-bonds giving the chance to develop more or less weak inter-
actions with macromolecules on the place of biological action. There is no visible 
physicochemical reason on the practical ineffectiveness of compounds 6i and 6q. 
Further investigations about the relationship of biological properties with physico-
chemical behaviors will be undertaken in the near future in our laboratories.
Conclusions
A newly designed branch of bis(arylidene)-4-cyclanones is described here in this 
article. The structure of this new group is based on 4-hydroxycyclohexanone, which 
was converted to the title-compounds, 2,6-bis(arylidene)-4-hydroxycyclohex-
anone (6) species under the conditions of the Claisen-Schmidt condensation reac-
tion. Series 6 and its derivatives 15, 18, 19 were evaluated against three malignant 
experimental cancer cell lines in vitro: A2780 (ovarian), C33A (cervix) and MDA-
MB-231 (breast). Antiproliferative biodata were obtained beside cisplatin as a ref-
erence drug in the form of tumor-growth-inhibition percentage in three different 
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concentrations. Structure–activity analysis revealed, that the best performer in this 
study is (E,E)-2,6-bis(3′-nitrobenzylidene)-4-hydroxycyclohexanone (6h) with  IC50 
values of 0.68, 0.69 and 0.92 μM, respectively, compared to cisplatin with 1.30, 3.69 
and 19.13 μM. Calculations were performed on computed compounds in order to 
obtain a relationship/correlation between biodata and physicochemical parameters. 
The best performer in this respect was 6p and 6o, in which case it was possible to 
predict improved bioavailability compared to curcumin. Acylation of the functional 
group at position 4 with chloroacetyl chloride was successful from pharmacological 
point of view. It led us to very effective acyl derivatives. It was possible for instance 
to increase the efficacy of 6a with the introduction of the chloroacetyl moiety into 
the structure of compound 19: inhibition ability grew dramatically from the 30 μM 
concentration down to the 0.3  μM. We have selected some of these derivatives 
for CD spectroscopic investigation in order to see whether they show any interac-
tion to natural DNA. Based on our CD spectroscopic data, we conclude that these 
Fig. 4  CD and UV titration of 0.033  mg/ml chicken erythrocyte DNA (black curve) with 5  mM cur-
cumin or curcuminoid stock solution (final concentrations are: 16.66 µg/mL, 25 µg/mL and 33.33 µg/mL, 
respectively)
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derivatives do not bind to DNA in vitro. Their antiproliferative effect is not due to 
their interaction with DNA.
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